BioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate Update
BLRX- Reports continued progress in the evaluation of assets for potential pipeline expansion in the areas of oncology and rare disease; transaction targeted for 2025 - - Provides updated and extended cash runway guidance into H1 2027 - - Management to host conference call today, August 14th,...
BioLineRx to Report Second Quarter 2025 Results on August 14, 2025
BLRXManagement to Hold Conference Call at 8:30 a.m. EDT TEL AVIV, Israel, Aug. 7, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a development stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it will release...
12 Health Care Stocks Moving In Monday's Pre-Market Session
BLRX12 Health Care Stocks Moving In Monday's Intraday Session
BLRXDow Edges Higher; Dell Shares Fall After Q1 Results
BLRXWhy Is Nano-Cap BioLineRx Stock Surging On Friday?
BLRXBioLineRx shares new data from its Phase 2 pancreatic cancer trial, showing strong response rates and durable outcomes with motixafortide combination.
Nasdaq Down 100 Points; Chicago PMI Dips In May
BLRX12 Health Care Stocks Moving In Friday's Pre-Market Session
BLRXWhy UiPath Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket
BLRXMarket-Moving News for May 30th
BLRXBioLineRx Reports Long-Term Tumor Control in Some Patients From New Pancreatic Cancer Combo Trial
BLRXHC Wainwright & Co. Reiterates Buy on BioLine Rx, Maintains $26 Price Target
BLRXBioLine Rx Q1 2025 EPS $0.00 May Not Be Comparable To $(1.20) Estimate, Sales $255.00K Vs. $6.86M YoY
BLRXA Look at BioLine Rx's Upcoming Earnings Report
BLRXBioLineRx Ltd., Merck Granted U.S. Patent #12291570 Treatment of metastatic pancreatic adenocarcinoma
BLRXJones Trading Downgrades BioLine Rx to Hold
BLRXHC Wainwright & Co. Maintains Buy on BioLine Rx, Raises Price Target to $26
BLRXUncovering Potential: BioLine Rx's Earnings Preview
BLRXHC Wainwright & Co. Reiterates Buy on BioLine Rx, Maintains $21 Price Target
BLRXBioLineRx Announces Oral Presentation On Data From Phase 1 Clinical Trial Evaluating Motixafortide For CD34+ Hematopoietic Stem Cell Mobilization For Gene Therapies In Sickle Cell Disease At ASH 2024
BLRXBioLineRx Seeks FDA Nod For Stem Cell Mobilization Candidate
BLRXBioLineRx (NASDAQ: BLRX) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its product candidate Motixafortide in stem cell mobilization (SCM) for autologous bone marrow transplantation for multiple myeloma patients.
BioLineRx Announces Submission Of New Drug Application To FDA For Motixafortide In Stem Cell Mobilization
BLRX